Merck, Inc.
🇵🇭Philippines
Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-03-09
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 179
- Registration Number
- NCT00105157
A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED)
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-02-28
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00104364
Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-02-23
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 107
- Registration Number
- NCT00104052
MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-02-16
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1208
- Registration Number
- NCT00103857
Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-02-15
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 72
- Registration Number
- NCT00103714
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
- First Posted Date
- 2004-12-24
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00100152
A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-12-23
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 206
- Registration Number
- NCT00100048
Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers
Phase 1
Completed
- Conditions
- First Posted Date
- 2004-12-15
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00099450
- Locations
- 🇺🇸
Quintiles Phase I Services, Lenexa, Kansas, United States
MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)
Phase 1
Terminated
- Conditions
- First Posted Date
- 2004-12-13
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00099346
An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-12-02
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT00097929
© Copyright 2024. All Rights Reserved by MedPath